Simplified assessment of castration-induced pain in pigs using lower complexity algorithms.

Pigs are raised on a global scale for commercial or research purposes and often experience pain as a by product of management practices and procedures performed. Therefore, ensuring pain can be effectively identified and monitored in these settings is critical to ensure appropriate pig welfare. The Unesp-Botucatu Pig Composite Acute Pain Scale (UPAPS) was validated to diagnose pain in pre-weaned and weaned pigs using a combination of six behavioral items. To date, statistical weighting of supervised and unsupervised algorithms was not compared in ranking pain-altered behaviors in swine has not been performed. Therefore, the aim of this study was to verify if supervised and unsupervised algorithms with different levels of complexity can improve UPAPS pain diagnosis in pigs undergoing castration. The predictive capacity of the algorithms was evaluated by the area under the curve (AUC). Lower complexity algorithms containing fewer pain-altered behaviors had similar AUC (90.1-90.6) than algorithms containing five (89.18-91.24) and UPAPS (90.58). In conclusion, utilizing a short version of the UPAPS did not influence the predictive capacity of the scale, and therefore it may be easier to apply and be implemented consistently to monitor pain in commercial and experimental settings.

A systematic review of reminder and guidance systems for Alzheimer's Disease and Related Dementias patients: context, barriers and facilitators.

Purpose. To present the latest available research assessing the actual impact of reminder and guidance technologies for daily activities in Alzheimer's Disease and Related Dementia's patients, outlining design implications for these technologies.Materials and methods. The search was conducted in the ACM Digital Library, IEEExplore, ScienceDirect, PubMed, Cochrane Library, Sage Journal, ResearchGate, and SemanticScholar. An iteratively-developed Boolean search string was built including up to 18 AND/OR terms across Four categories (Memory Aids, Technology, Daily Activities, Memory Impairment). We qualitatively analyzed the findings and discussions of the findings reported in 40 studies in our corpus to determine common barriers to, and facilitators of, effective intervention implementation and adoption.Results. Forty studies fulfilled the inclusion and exclusion criteria. In existing studies, individuals with Alzheimer's Disease and Related Dementias understand the usefulness of different functions that can be provided within an app to assist with everyday tasks. There was a high level of heterogeneity regarding the studies' location, duration, and evaluation methodology.Conclusions. There is a need for assistive reminder and guidance technologies to be tailored towards autonomy, identity and personalization. Future work should include motivating features to aid during mood changes and feelings of insecurity.IMPLICATIONS FOR REHABILITATIONIn existing studies, older adults with cognitive impairment understand the usefulness of different functions that can be provided within an app to assist with everyday tasks.There is a high level of heterogeneity regarding the studies' location, duration, and evaluation methodology.There is ample need for these reminder technologies to be tailored towards autonomy, identity and personalization.Future work should include motivating features to aid during mood changes and feelings of insecurity.

Virtual Reality Exposure Treatment in Phobias: a Systematic Review.

We compare the relative efficacy of virtual reality therapy exposure (VRET) versus in vivo therapy exposure among individuals suffering from phobias. A systematic search was completed up to 03 April 2020, using the following databases: ACM Digital Library, ResearchGate, IEEE, Science Direct, MIT PressJournals, Center for Direct Scientific Communication (CCSD) and Mary Ann Liebert Publishers. Five authors searched the databases using the following terms: Virtual Reality, Phobia, Mental health, Computing, Therapy, HMD, CAVE, Virtual ambient, in virtuo, Avoidance, Exposure, VRET, in vivo, Anxiety, Agoraphobia, Social Phobia, Stimuli, Cognitive-behaviour. All studies that evaluate the effect of in virtuo exposure towards phobia rehabilitation were selected. By reviewing the article, each author then applied the inclusion and exclusion criteria, and 30 articles were selected. Data extracted included the number of samples, amount of sessions, study variables that may affect the final outcome, therapy technology. The data provided was synthesized using a meta-analysis based on the results. The results demonstrated a positive outcome of Virtual Reality Exposure Treatment in the treatment of most phobias. In contrast, some of these treatments did not work for a few specific phobias in which the standard procedures were more effective. The findings suggest that for some specific phobias treatment, Virtual Reality Exposure Treatment does not reach the in vivo exposure level of immersion and presence. Further research is needed to perform studies with higher-dimension samples, since many papers report a low sample size and that is probably why many of them have inconclusive results.

Increased lipid synthesis in the culture of Chlorella homosphaera with magnetic fields application.

This study aimed to investigate the influence of different intensities (15, 30 and 60 mT) and exposure times (1 h d-1, 24 h d-1) of magnetic fields (MF) on the stimulation of lipid synthesis by the microalga Chlorella homosphaera. The growth and biochemical characterization of protein, carbohydrate and lipid content were determined. Biomass concentration increased by 20.6% (30 mT, 1 h d-1) and 12.4% (60 mT, 1 h d-1) in the presence of MF. However, biomass decreased by 33.0% (15 mT, 1 h d-1) in relation to control cultivation (CC). The stress caused by the MF application stimulated lipid synthesis and biomass production. In all evaluated conditions, MF application showed a positive effect on lipid production; the application of 60 mT or 30 mT for 1 h d-1 increased lipid productivity by 108.4% and 135.1%, respectively. MF application with ferrite magnets was thus efficient to stimulate lipid synthesis.

Knee isokinetic muscle strength and balance ratio in female soccer players of different age groups: a cross-sectional study.

Background: As a consequence of years of soccer training and sexual maturation, there is an increase in lower body muscle mass and strength especially in the knee extensors and flexors muscles. In this context, the lack of knee joint stability, resulting from strength imbalance between knee extensor and flexors muscles, has been associated with knee injuries. The aim of this study was to compare the knee flexor and extensor muscle peak torque, average power, contralateral deficit, conventional and functional balance ratios of female soccer players from different age groups.Methods: Sixty-six female soccer players were divided into four groups: under 13 (U13), under 15 (U15), under 17 (U17) years old and professional (PRO). Flexor and extensor knee muscle strength in concentric and eccentric actions of both limbs were assessed using isokinetic dynamometer.Results: For the dominant limb, the knee concentric extensor muscles peak torques, assessed at 60 and at 240 deg/sec, and the average power of U15 group were significantly higher than U13 group. Extensor muscle average power of the PRO group was higher than U17. Dominant knee flexor average power of U15 was significantly higher than the U13 group. Peak torque at 60 deg/sec and 240 deg/sec and average power of the PRO group were higher than the U17 group. No differences were found regarding the eccentric action for flexor and extensor muscles. Conventional and functional balance ratios were similar among all age group, except for U13, which presented higher values than the U15 group for the dominant limb.Conclusions: The greatest improvement in muscular performance occur when the athlete starts practicing soccer (after U13) and when they become professional (after U17) and the balance ratios, and muscle balance ratios remain stable in all age groups, although they are below the recommended level in the literature, which may increase the risk for lower limb injury.

The effects of low level laser therapy on injured skeletal muscle

The main purpose of the present study was to investigate the effects of low-level laser therapy (LLLT) used in two different fluencies on injured skeletal muscle after cryolesion by means of histopathological analysis and immunohistochemistry for COX-2. A total of sixty male Wistar rats were randomly distributed into three groups: injured animals without any treatment; 808 nm laser treated group, at 10 J/cm² and 808 nm laser treated group, at 50 J/cm². Each group was divided into two different subgroups (n=10) on days 6 and 13 post-injury. The results showed that the animals irradiated with laser at 10 J/cm² or 50 J/cm² presented the areas with cell infiltrate and pointed out to minor and mild areas with destroyed zones compared with the control group. Also, a COX-2 downregulation was noticed in the groups exposed to laser at two fluences evaluated in this study. Significant statistically differences (p<0.05) were noticed to collagen deposition in the laser treated animals, with the fluence of 50 J/cm² when compared to the other groups on day 13 post-surgery. Taken together, these results suggested that laser therapy could have positive effects on muscle repair in the rats after cryolesion.

Questões relevantes para a aprovação de medicamentos biossimilares / Relevant issues to biossimilars licensing

Medicamentos genéricos podem ser introduzidos a baixo custo no mercado quando a patente do medicamento inovador expira. Os resultados dos testes que demonstram a segurança e eficácia do produto inovador podem ser extrapolados para o genérico, simplificando sua aprovação. Este paradigma não pode ser aplicado aos biofármacos, grandes moléculas de difícil caracterização, onde pequenas alterações no processo de manufatura influenciam as propriedades biológicas e clínicas do produto e podem resultar em diferenças nos seus perfis de eficácia e segurança. Não sendo possível demonstrar a identidade entre biofármacos, eles não podem ser aprovados como simples genéricos e necessitam regulamentação específica. Neste trabalho foram feitos um levantamento bibliográfico das principais questões envolvidas na aprovação de versões similares de biofármacos e uma análise comparativa da situação regulatória nos principais mercados - EUA e União Europeia - a partir de legislação, projetos de lei, diretrizes e referências técnicas de suas agências regulatórias - FDA (Food and Drug Administration) e EMEA (European Medicines Agency), respectivamente, visando à discussão do caso brasileiro. A partir da legislação e diretrizes estudadas conclui-se que, apesar de Brasil, Europa e Estados Unidos estarem em estágios distintos de definição de sua estrutura regulatória para biossimilares, é possível identificar algumas semelhanças nas abordagens seguidas, como a necessidade de tratamento diferenciado para cada classe de produto (ou um enfoque caso a caso) e de um exercício de comparabilidade passo a passo, cujos resultados definirão a quantidade de dados e estudos clínicos e não clínicos necessários. Entretanto, questões como intercambialidade e substituição automática dos produtos de referência por biossimilares ainda não estão claramente definidas. Do ponto de vista sanitário, a Europa apresenta uma postura mais conservadora, enquanto que EUA e Brasil parecem estar construindo um arcabouço mais flexível. Ao lado das questões sanitárias, entretanto, destacam-se as questões econômicas, de grande importância na legislação dos EUA e Europa e não abordadas na regulamentação brasileira - o que pode trazer insegurança aos produtores interessados neste mercado.

When the patent of a drug expires, low cost generics may be introduced in market. Trial results that demonstrate the safety and efficacy of the reference product can be extrapolated to the generic, simplifying the approval process. This paradigm cannot be applied to biopharmaceutical products, large molecules difficult to be characterized. Minor changes in the production process can influence the biological and clinical properties of the product and result in differences in efficacy and safety profiles. It is not possible to demonstrate the identical nature of biopharmaceuticals arising from different manufacturing sources, so they cannot be approved as simple generics and need specific regulation. A bibliographical survey of the main issues involved in the approval of similar versions of biopharmaceuticals was performed as well as a comparative analysis of the regulatory situation in the largests pharmaceutical markets - U.S. and European Union - based on legislation, draft laws, guidelines and technical references issued by their regulatory agencies - FDA (Food and Drug Administration) and EMEA (European Medicines Agency), respectively, in order enlight the discussion now taking place in Brazil. Based on the laws and guidelines studied, it is concluded that, although Brazil, Europe and the United States are at different stages of setting their regulatory framework for biossimilars, it is possible to identify some similarities in approach, such as the need for different treatment for each product class (or a case by case focus) and a step by step comparison exercise, the results of which will define the amount of data and non-clinical and clinical studies required. However, issues such as interchangeability and automatic substitution of biossimilars for reference products are not yet clearly defined. From the sanitary point of view, Europe has a more conservative posture, while the U.S. and Brazil seem to be building a more flexible framework. Besides the health issues, however, we highlight the economic issues, of great importance in Europe and U.S. legislation, and not addressed in the Brazilian regulation - which can bring insecurity to producers interested in this market.

Relevant issues to biossimilars licensing.

When the patent of a drug expires, low cost generics may be introduced in market. Trial results that demonstrate the safety and efficacy of the reference product can be extrapolated to the generic, simplifying the approval process. This paradigm cannot be applied to biopharmaceutical products, large molecules difficult to be characterized. Minor changes in the production process can influence the biological and clinical properties of the product and result in differences in efficacy and safety profiles. It is not possible to demonstrate the identical nature of biopharmaceuticals arising from different manufacturing sources, so they cannot be approved as simple generics and need specific regulation. A bibliographical survey of the main issues involved in the approval of similar versions of biopharmaceuticals was performed as well as a comparative analysis of the regulatory situation in the largests pharmaceutical markets - U.S. and European Union - based on legislation, draft laws, guidelines and technical references issued by their regulatory agencies - FDA (Food and Drug Administration) and EMEA (European Medicines Agency), respectively, in order enlight the discussion now taking place in Brazil. Based on the laws and guidelines studied, it is concluded that, although Brazil, Europe and the United States are at different stages of setting their regulatory framework for biossimilars, it is possible to identify some similarities in approach, such as the need for different treatment for each product class (or a case by case focus) and a step by step comparison exercise, the results of which will define the amount of data and non-clinical and clinical studies required. However, issues such as interchangeability and automatic substitution of biossimilars for reference products are not yet clearly defined. From the sanitary point of view, Europe has a more conservative posture, while the U.S. and Brazil seem to be building a more flexible framework. Besides the health issues, however, we highlight the economic issues, of great importance in Europe and U.S. legislation, and not addressed in the Brazilian regulation - which can bring insecurity to producers interested in this market.

Políticas públicas educativas aplicadas en contextos urbanos y rurales: estudio de caso / Applied educative public policies in rural urban contexts: case study

El texto presenta la investigación sobre la forma en la cuál se están aplicando las políticas públicas educativas en los espacios urbanos y rurales de Bolivia. La forma en la cuál se gestionan los procesos de enseñanza-aprendizaje, las condiciones materiales en las que se desarrolla la vida en las escuelas o cómo participan las juntas escolares en la gestion educativa

Políticas públicas educativas aplicadas en contextos urbanos y rurales: estudio de caso / Applied educative public policies in rural urban contexts: case study

El texto presenta la investigación sobre la forma en la cuál se están aplicando las políticas públicas educativas en los espacios urbanos y rurales de Bolivia. La forma en la cuál se gestionan los procesos de enseñanza-aprendizaje, las condiciones materiales en las que se desarrolla la vida en las escuelas o cómo participan las juntas escolares en la gestion educativa